Navigation Links
PharmAthene Reports Third Quarter 2013 Financial And Operational Results
Date:11/7/2013

, in May 2013, the Delaware Supreme Court issued its ruling on the appeal in our litigation with SIGA Technologies, affirming the Court of Chancery's finding that SIGA was liable for breach of contract, reversing its finding of promissory estoppel, and remanding the case back to the Court of Chancery to reconsider the appropriate remedy and award of attorney's fees and expert witness costs in light of the Supreme Court's opinion. For more information about PharmAthene, please visit www.PharmAthene.com.

About TheracloneTheraclone is a biopharmaceutical company focused on the discovery and development of novel, monoclonal antibody therapeutics for diseases that are devastating for patients and their families and which are a significant threat to human health. Theraclone leverages its proprietary antibody discovery technology, I-STAR™ (In-Situ Therapeutic Antibody Rescue), to identify rare human antibodies that may be developed into antibody product candidates that are potentially safer and more effective than current therapies. Theraclone has a portfolio of innovative antibodies in clinical and preclinical development targeting serious medical conditions with a significant unmet medical need and a primary focus on infectious disease and cancer, which include:

  • TCN-032 - a recombinant fully human monoclonal antibody for the treatment of patients hospitalized with serious influenza
  • TCN-202 - a recombinant fully human monoclonal antibody for the treatment and prevention of cytomegalovirus, or CMV infections
  • For more information about Theraclone, please visit www.theraclone-sciences.com. On August 1, 2013, Theraclone and PharmAthene (NYSE MKT: PIP) announced a definitive merger agreement.

    Important Additional Information about the Proposed MergerThis communication is being made in connection with the proposed merger involving PharmAthene
    '/>"/>

    SOURCE PharmAthene, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8 9

    Related medicine technology :

    1. PharmAthene to Present at Rodman & Renshaw Annual Global Investment Conference
    2. PharmAthene and Theraclone Sciences Announce Merger Agreement to Create Diversified Biologics Company Targeting Government and Commercial Markets
    3. PharmAthene Reports First Quarter 2013 Financial And Operational Results
    4. New Data Show PharmAthenes Recombinant Bioscavenger Binds To A Broad Spectrum Of Chemical Nerve Agents
    5. SIGA Technologies Files Notice of Appeal in PharmAthene Litigation
    6. Pharmacyclics Reports Third Quarter 2013 Results
    7. CareFusion Reports First Quarter Fiscal 2014 Results
    8. Sequenom, Inc. Reports Financial Results For The Third Quarter Of 2013
    9. Arena Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2013 Financial Results
    10. Nektar Therapeutics Reports Financial Results for the Third Quarter of 2013
    11. ANI Pharmaceuticals Reports Net Revenues of $7.8 million, adjusted Non-GAAP EBITDA of $1.7 Million, and EPS of $0.13 for the Third Quarter Ended September 30, 2013
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:7/31/2014)... 2014 STAAR Surgical Company (NASDAQ: ... implantable lenses and delivery systems for the eye today ... 2014 of $20.0 million, a 10% increase over $18.2 ... a constant currency basis, revenues grew 11% during the ... of 2013.  The effect of foreign currency exchange reduced ...
    (Date:7/31/2014)... MONROVIA, Calif., July 31, 2014 Xencor ... biopharmaceutical company developing engineered monoclonal antibodies for the ... and cancer, today reported financial results for the ... review of recent business highlights. "In ... the American Thoracic Society 2014 International Conference (ATS) ...
    (Date:7/31/2014)... July 31, 2014  Alexza Pharmaceuticals, Inc. (Nasdaq: ... on its pipeline and new product development efforts. In ... initiate a Phase 2a study of AZ-002 (Staccato ... the management of patients with acute repetitive seizures. ... -based product candidates for development - AZ-008 and ...
    Breaking Medicine Technology:STAAR Surgical Reports 10% Second Quarter Revenue Growth 2STAAR Surgical Reports 10% Second Quarter Revenue Growth 3STAAR Surgical Reports 10% Second Quarter Revenue Growth 4STAAR Surgical Reports 10% Second Quarter Revenue Growth 5STAAR Surgical Reports 10% Second Quarter Revenue Growth 6STAAR Surgical Reports 10% Second Quarter Revenue Growth 7STAAR Surgical Reports 10% Second Quarter Revenue Growth 8STAAR Surgical Reports 10% Second Quarter Revenue Growth 9STAAR Surgical Reports 10% Second Quarter Revenue Growth 10STAAR Surgical Reports 10% Second Quarter Revenue Growth 11STAAR Surgical Reports 10% Second Quarter Revenue Growth 12STAAR Surgical Reports 10% Second Quarter Revenue Growth 13STAAR Surgical Reports 10% Second Quarter Revenue Growth 14STAAR Surgical Reports 10% Second Quarter Revenue Growth 15STAAR Surgical Reports 10% Second Quarter Revenue Growth 16STAAR Surgical Reports 10% Second Quarter Revenue Growth 17STAAR Surgical Reports 10% Second Quarter Revenue Growth 18STAAR Surgical Reports 10% Second Quarter Revenue Growth 19STAAR Surgical Reports 10% Second Quarter Revenue Growth 20STAAR Surgical Reports 10% Second Quarter Revenue Growth 21STAAR Surgical Reports 10% Second Quarter Revenue Growth 22STAAR Surgical Reports 10% Second Quarter Revenue Growth 23STAAR Surgical Reports 10% Second Quarter Revenue Growth 24STAAR Surgical Reports 10% Second Quarter Revenue Growth 25STAAR Surgical Reports 10% Second Quarter Revenue Growth 26STAAR Surgical Reports 10% Second Quarter Revenue Growth 27STAAR Surgical Reports 10% Second Quarter Revenue Growth 28STAAR Surgical Reports 10% Second Quarter Revenue Growth 29STAAR Surgical Reports 10% Second Quarter Revenue Growth 30STAAR Surgical Reports 10% Second Quarter Revenue Growth 31Xencor Reports Second Quarter 2014 Financial Results 2Xencor Reports Second Quarter 2014 Financial Results 3Xencor Reports Second Quarter 2014 Financial Results 4Xencor Reports Second Quarter 2014 Financial Results 5Xencor Reports Second Quarter 2014 Financial Results 6
    ... 2011 Results of the first randomized, placebo-controlled long-term ... dyskinesia or involuntary movements in mid-to-late stage Parkinson,s disease. ... the 63rd Annual Meeting of the American Academy ... "Our findings over a two-year treatment period suggest ...
    ... HELENA, Mont., April 12, 2011 The association representing ... a new, bipartisan bill in Congress to repeal the ... and services.   "It is imperative that ... health of both Medicare patients and local businesses in ...
    Cached Medicine Technology:Investigational Drug May Reduce Involuntary Movements in People With Parkinson's Disease 2Investigational Drug May Reduce Involuntary Movements in People With Parkinson's Disease 3Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 2Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 3Montana Medical Equipment Providers Back New Congressional Bill to Repeal Flawed Medicare Bidding Program 4
    (Date:8/1/2014)... August 01, 2014 The American ... Gregg Harper (R-MS), and Peter Welch (D-VT), for ... Medicare Telehealth Parity Act of 2014, which improves ... this effort to improve healthcare access and affordability ... officer of ATA. "These cost-saving provisions are critical ...
    (Date:8/1/2014)... On Monday, June 30th, the Quirk ... in San Francisco, CA. Now in its fourth year, ... Union Square hotel. , “We are excited about returning ... with ACA compliance issues,” Quirk Healthcare Foundation Executive Director, ... attendees guidance with NextGen implementation and use, electronic records ...
    (Date:8/1/2014)... FRIDAY, Aug. 1, 2014 (HealthDay News) -- Although many parents ... many overlook a common choking hazard: food. Such ... wheeze and cough after eating a handful of nuts. ... not obvious if the coughing was related to his illness ... wasn,t a cold. A cashew had become lodged in his ...
    (Date:8/1/2014)... 01, 2014 Over the past ... from innovative technologies that have enabled cosmetic dentists ... tooth color. Moreover, the burgeoning elderly population has ... tooth ailments. Due to long-term use of medications, ... have demanded dental fillings, veneers and implants. As ...
    (Date:8/1/2014)... Oxford Gene Technology (OGT) is ... products include CytoSure heamatological cancer +SNP Array, CytoSure ... UPD array, CytoSure ISCA sample tracking spike-ins and ... such as targeted sequencing services, SureSeq Solid Tumour ... expression analysis, cytosure services and aCGH for CNV ...
    Breaking Medicine News(10 mins):Health News:ATA Applauds Bill on Medicare Telemedicine Improvements 2Health News:Quirk Healthcare Foundation Hosts Fifth Annual California NextGen User Symposium and Launches First Annual Florida NextGen User Symposium 2Health News:Food Is a Common Choking Hazard for Kids, Doctor Says 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 2Health News:Cosmetic Dentists in the US Industry Market Research Report from IBISWorld Has Been Updated 3Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 2Health News:Oxford Gene Technology Market Size, Share, Analysis, Trends and Forecasts 2014 3
    ... on the Atkins low-carbohydrate diet lose more weight than those ... pressure and cholesterol levels dropped considerably. ,On average, ... months. The average weight loss was 5.7 pounds for women ... diet and 3.5 pounds for those following the Zone weight-loss ...
    ... that a plane accident that left a father and young ... a suicide// crash. ,Two people were killed Monday ... the edge of a small local airport in Bedford - ... destroyed the house of the former mother-in-law of the divorced ...
    ... greens and beans aren't the only foods that pack ... healthy// start to pregnancy. ,Researchers now have ... a full day's worth of the nutrient in a ... week's online edition of the journal PNAS, Proceedings of ...
    ... the Chulalongkorn Hospital here removed a 60-cm-long sword that had ... and exited// near his left ear, news reports said Wednesday. ... a stable condition after the sword's removal from his face ... Tuesday, reported the Thai Rath newspaper. ,Ronnachai received ...
    ... Institute for Biological Studies, have discovered that silencing a gene ... reduce insulin resistance, in animal models, it will also help ... , The peptide in question is ucocortin 3. This ... produced in the insulin secreting cells of the pancreas and ...
    ... of a brain system that regulates appetite. The study also ... new drug therapies to help individuals lose weight. ... around 30 percent are obese. The study conducted by scientists ... the March issue of Cell Metabolism. ,The research ...
    Cached Medicine News:Health News:Atkin’s Low-carb Diet Best for Weight Los 2Health News:Scientists Genetically Engineer Tomatoes With Enhanced Folate Content 2Health News:Scientists Explore Ways to Reduce Insulin Resistance by ‘handcuffing’ Gen 2Health News:Targeting SOCS-3 can Control Obesity 2
    ... Basic ergonomic chairs with concave seats ... • Select options like seats, backrests, ... BTC/1Q chairs are recommended for the ... room, static control, health care and ...
    ... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
    ... with concave seats and standard-sized backrests ... like seats, backrests, armrests, and casters ... recommended for the following environments: industry, ... health care and office. • With ...
    ... chairs with concave seats and large ... options like seats, backrests, armrests, and ... BE Series for top performance in ... education, laboratory, clean room, static control, ...
    Medicine Products: